Stocksigma LogoStocksigma Logo

Viyash Scientific Reports Strong Q2 FY27 Results with PAT Growth of 16.1% YoY

Viyash Scientific reported Q2 FY27 revenue from operations of ₹9,879 Mn, up 16.2% YoY and 4.4% QoQ. Pre-ESOP EBITDA rose 10.3% YoY to ₹2,077 Mn with a

Viyash Scientific Reports Strong Q2 FY27 Results with PAT Growth of 16.1% YoY

Sequent Scientific Ltd · Press Release · 14 Nov 2026, 12:04 am

Viyash Scientific Reports Strong Q2 FY27 Results with PAT Growth of 16.1% YoY Viyash Scientific reported Q2 FY27 revenue from operations of ₹9,879 Mn, up 16.2% YoY and 4.4% QoQ. Pre-ESOP EBITDA rose 10.3% YoY to ₹2,077 Mn with a 21.0% margin. PAT grew 16.1% YoY to ₹847 Mn, while Adjusted PAT reached ₹1,110 Mn. For H1 FY27, revenue climbed 17.8% YoY to ₹19,343 Mn and PAT surged 49.4% YoY to ₹1,639 Mn. Balance sheet strength improved with Net Debt/EBITDA declining to 0.0x from 0.7x last year. The company completed its BioForLife acquisition in Italy and is expanding oncology and API capacities.

Original exchange filing (PDF)

More announcements from Sequent Scientific Ltd

All Sequent Scientific Ltd announcements